Getinge enters into commercial agreement with TSO3 for Sterizone VP4 steriliser

TSO3 technology fills a gap in Getinge's portfolio and is a natural fit for the commercial team

Getinge Infection Control has signed a commercial agreement with TSO3, a Canadian innovator in sterilisation technology for medical devices in healthcare settings, in support of the launch of the Sterizone VP4 sterilisation system. The non-exclusive agreement covers multiple markets in which Getinge has significant market share, including North America and other selected markets. Efforts to launch the product will begin immediately.

The Sterizone VP4 steriliser developed by TSO3 is a dual sterilant, low temperature sterilisation system that utilises vaporised hydrogen peroxide (H2O2) and ozone. Its single cycle can sterilise a large number and wide range of compatible devices, thereby allowing for cost effective error-free sterilisation process. TSO3's Dynamic Sterilant Delivery System automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature.

With its large 75 lbs load capacity and a short cycle time, the Sterizone VP4 Sterilizer can enhance throughput and lower sterilisation costs. It was cleared for commercialisation in the US in December 2014.

'We are extremely pleased to have Getinge Infection Control representing our Sterizone technology,' said Ric Rumble, President and CEO of TSO3. 'Getinge has watched the progression of our technology through the US regulatory process and with US clearance now in hand, both organisations see the opportunity to launch this superior technology in North America and selected additional markets.'

'Getinge Infection Control is the world leader in sterile reprocessing of reusable medical devices,' stated Andrew Ray, President and CEO of Getinge Infection Control North America. 'The TSO3 technology fills a gap in our portfolio and is a natural fit for our commercial team.

'Our entire organisation is anxious to get started assisting our mutual customers understand how this technology improves their process and reduces the cost of sterilisation while improving patient outcomes.'

Companies